AVENUESAI LIMITED Valuation

CCAVENUE · Financial Services · Current price ₹13.85

Full stock page
DocStoX fair value
₹20
low confidence · 45/100
Current price
₹16
Upside to fair value
+22.8%
Estimate range
₹10 – ₹22
P/E ratio
17.3x
P/B ratio
1.1x
Model it yourself — Earnings Yield Calculator
Opens pre-filled with AVENUESAI LIMITED's latest numbers.

Is AVENUESAI LIMITED undervalued?

We estimate the fair value of AVENUESAI LIMITED at ₹20 per share, against a market price of ₹16. That puts the share price about +22.8% below our estimate, at low confidence. This is our view of what the business is worth, not a target price or a forecast of where the share price will go.

How this fair value is calculated

This estimate comes from 3 methods: Discounted cash flow (2-stage) (₹10), Fair multiple (P/E) (₹28), Residual income (excess return on book) (₹12). These methods disagree materially, so the estimate is their midpoint rather than a weighted blend, and the disagreement is part of the finding. The full working, including the assumptions and what data was missing, is set out below.

The range around this estimate

Our estimate for AVENUESAI LIMITED spans ₹10 to ₹22. That range is wide, which is the honest signal here: read the range rather than the single number. A margin of safety means buying meaningfully below the estimate: the wider the range, the more room the assumptions leave for error.

Valuation multiples

AVENUESAI LIMITED trades at a P/E of 17.3x and a P/B of 1.1x, with a dividend yield of 0.3%. Multiples are most useful compared against the company's own history and its sector peers — see the peer comparison for context.

How we got this fair value

Every number below is part of the same estimate for AVENUESAI LIMITED. Nothing here is a target price or a forecast of where the share price will go.

Low confidence45/100floor: no better than this

The inputs are thin or the models disagree sharply. This is our least reliable kind of estimate, so read the range rather than the single number.

Estimate range ₹10 – ₹22

Why this method for this business

The business is asset-light with strong earnings power, making DCF and relative PE appropriate. Residual income adds a book-value lens for completeness.

The models behind the number

These methods disagree materially, so the estimate is their plain midpoint rather than a weighted blend. The disagreement is itself the finding.

Discounted cash flow (2-stage)
₹10equal weight

Intrinsic value from 2-stage discounted cash flows (primary for asset-light / normal businesses); FCFE path

Fair multiple (P/E)
₹28equal weight

downweighted: 137% from committee consensus (₹12)

Residual income (excess return on book)
₹12equal weight

Book value plus the present value of returns earned above the 10.6% cost of equity

  • Discounted cash flow (2-stage) is primary for asset-light businesses; residual income is secondary for book-value residual returns; relative PE is used for multiple comparison

What was missing

  • Lack of historical P/E data for normalization
  • Limited analyst coverage for multiple validation

What drives it

31 inputs, grouped by how strong each claim is
ReportedRead from filings or market data. Verifiable, not our opinion.
FCF_0 (normalized)
155 ₹cr

fcf_norm (median ≤5y positive)

Net debt
430 ₹cr

gross debt (cash n/a)

Sector-median P/E
19.66×

peer-median

Peers used
395

peer-median

EPS (TTM)
0.9 ₹/share

computed

ROE (normalized)
4.8%

computed

Book value / share
13.6 ₹

reported

MacroEconomy-wide input, not company-specific.
Discount rate (r)
15.53%

COE (building-block)

Beta
1.15

bottom-up industry

Cost of equity
10.6%

building-block

AssumptionA forward input the model chose. Reasonable people can disagree here.
Stage-1 start growth
30%

pat_cagr_5y

Fade shape
hard

lifecycle Hyper-Growth

Terminal growth (g)
4.99%

macro terminal × quality premium

Stage-1 years
12 y

lifecycle Hyper-Growth horizon

JudgementOur read of the evidence, not a measurement.
Lifecycle stage
Hyper-Growth

forecast engine (L20)

Quality premium
0.998×

moat None + capital allocation

Term: quality
-5.1%

quality 45/100 (weak/erratic returns) → discount

Term: growth
+40.0%

durable ~49% CAGR (ROCE 6% < 12% hurdle (growth not value-accretive)) → premium

Term: capital_allocation
+10.9%

capital allocation: rising ROCE funded by strong FCF → premium

Term: financial_strength
+8.0%

financial strength: effectively debt-free → premium

Term: history
+0.0%

history: no reliable own-history P/E → not used

Term: sector_rerating
+0.0%

sector re-rating: no sector-norm history → not used

Term: rate_regime
+1.2%

rates: risk-free 6.9% below ~7.1% normal → higher multiple

Term: risk
+0.0%

risk: no analyst-dispersion signal available → neutral (lowers confidence, not PE)

Moat
None

computed

Excess-return horizon
3 yrs

computed

DerivedFalls out of the inputs above: a model output, not an independent input.
Path
FCFE

computed (D/E vs 0.8)

Terminal-value fraction
0.384

PV_TV / (PV_1+PV_TV)

Premium vs sector
+61.0%

fundamentals + macro (not capped at own history)

Fair-multiple confidence
62%

data completeness + term agreement

Fair P/E
31.65×

sector median × ∏(1+term) — Dynamic Fair Multiple

Who computed this

A language model (qwen3:8b) selects the valuation method and the judgement inputs for AVENUESAI LIMITED: which models suit the business, the moat, the growth and margin assumptions. It does not produce the number. The fair value itself is computed in Python by a deterministic engine (version 2026.08.1) from those inputs, so the same inputs always give the same result and every figure above can be traced to a source.

Estimated 14 Sept 2026. Re-run as new financials and news arrive.

How we value stocks

We estimate what a business is worth from its own economics: cash flows, returns on capital, and a multiple justified by its quality, rather than from where the share price has been. A fair value estimate is a view, not a verdict, and it is only as good as the inputs listed above.

Read the full fair-value methodology

Understand the ratios

More on AVENUESAI LIMITED

DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.